IDEAYA Biosciences is shifting into a commercial oncology company, driven by the positive results of darovasertib in a phase 2 trial that showed improved progression-free survival (6.9 vs. 3.1 months). This supports their New Drug Application (NDA) submission and potential U.S. commercialization. With $1.24 billion in cash, IDEAYA can fund operations through 2030, advancing multiple proprietary drug combinations. Strategic collaborations, including with Roche, enhance their clinical and commercial development options, positioning the company for growth beyond darovasertib's approval in metastatic uveal melanoma treatment.
Pinterest director Benjamin Silbermann recently sold 93,750 shares of the company, generating approximately $1.8 million from the transaction. This sale could indicate a personal financial move or a strategic decision, but it may attract investor att...
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Trader Peter Brandt highlighted $1.6572 as a critical resistance level for XRP, currently priced at $1.5230, suggesting a potential breakout if surpassed. The chart hints at a possible cup-and-handle pattern, a bullish signal, but Brandt did not conf...
